Akromegalide Ortalama Trombosit Volümünün Değerlendirilmesi ve Tedavi ile İlişkisi

Year 2020, Volume: 17 Issue: 3, 355 - 359, 25.12.2020

Özlem Zeynep Akyay Alev Selek Adnan Batman Berrin Çetinaslan Zeynep Cantürk İlhan Tarkun

Abstract

Amaç: Ortalama trombosit volümü (MPV) ateroskleroz ve trombotik olaylar için bağımsız bir risk faktörüdür. Çalışmamızda akromegalik hastalarda MPV düzeyini ve tedavi ile ilişkisini değerlendirmeyi amaçladık.
Materyal ve Metod: Çalışmamızda akromegali hastalarında tedavi öncesi, tedavi sonrası ve remisyondan 2 yıl sonraki MPV düzeylerini değerlendirdik. Ayrıca sonuçları kontrol grubu ile karşılaştırdık. Kliniğimizde takipli 80 akromegali hastası yaş ve cinsiyet açısından benzer kontrol grubu ile retrospektif olarak kıyaslandı. Preoperatif ve postoperatif MPV değerleri ile medikal tedavi alan hastalarda hastalık kontrolünden iki yıl sonraki MPV değerleri karşılaştırıldı.
Bulgular: Diyabetik ve non-diyabetik akromegali hastalarında MPV düzeyi kontrol grubuna göre anlamlı oranda yüksekti (p=0,02). Postoperatif kür sağlananlarda postoperatif MPV preoperatif MPV’ye göre anlamlı oranda düşüktü (p=0,001). Cerrahi tedavi başarısızlığından sonra medikal tedavi ile hastalık kontrolü sağlananlarda MPV düzeyi cerrahi ile kür sağlananlarla ameliyattan iki yıl sonra bile benzerdi (p=0,001).
Sonuç: Bulgularımız, MPV'nin akromegali hastalarında ateroskleroz ve inflamasyon için yararlı bir belirteç olabileceğini düşündürmektedir.

Anahtar kelimeler: Akromegali, Ateroskleroz, İnflamasyon, Ortalama trombosit volümü

Keywords

Acromegaly, Atherosclerosis, İnflammation, Mean Platelet Volume

Assessment of Mean Platelet Volume in Acromegaly And Its Relation With The Treatment

Abstract

Background: Mean platelet volume (MPV) is an independent risk factor of atherosclerosis and thrombotic events. We aimed this study evaluates the levels of MPV in acromegalic patients and its relationship with treatment.
Materials and Methods: In this study, we examined the levels of MPV in acromegalic patients before and after treatment and also at two years of remission. The results were also compared with a control group. A total of 80 patients treated at our clinic with the diagnosis of acromegaly age- and gender-matched nonacromegalic controls were reviewed retrospectively. Preoperative and postoperative MPV values as well as MPV values two years after controlling disease in patients with medical treatment were compared.
Results: MPV values were significantly higher in both the diabetic and non-diabetic acromegaly patients compared with the control subjects (p=0,02). Postoperative MPV values were significantly reduced compared to preoperative values in patients cured after surgery (p=0,001). Patients who achieved disease control with medical therapy after failure of surgical intervention demonstrated MPV values similar to those reported in patients cured with, even after two years from surgery (p=0,001).
Conclusions: Our findings suggested that MPV would be a beneficial marker for atherosclerosis and inflammation in patients with acromegaly.

Keywords

Acromegaly, Atherosclerosis, İnflammation, Mean Platelet Volume

References

• 1. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011; 17:1-44. 2. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lambert S, F. Casanueva, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-3148. 3. Wıllıam L, McGuffin WL, Phıllıp G, Ronald K, Wıllıam CR, Peter LF. Acromegaly and cardiovascular disorders: A prospective study. Ann Intern Med 1974;81:11–18 4. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone E, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000; 85:193-199. 5. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hyperten 1993; 6:260-270. 6. Sherlock M, Ayuk J, Tomlinson JW, Toogod AA, Aragon-Alason A, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocr Rev 2010; 31:301-342. 7. Kartal I, Oflaz H, Pamukcu B, Meriç M, Aral F, Özbey N, et al. Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 2010; 64:39-44. 8. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011;17:47-58. 9. Are´valo-Lorido JC, Carretero-Go´mez J, Villar-Vaca P. Mean platelet volume predicting carotid atherosclerosis in atherothrombotic ischemic stroke. Ir J Med Sci 2012;181:179-183. 10. Bath PM, Butterworth RJ. Palatelet size :measurement, phisology and vascular disease. Blood Coagul Fibrinolysis 1996; 7:157-161. 11. Sewell R, Ibbotson RM, Phillips R, Carson P. High mean platelet volume after myocardial infarction: is it due to consumption of small platelets? Br Med J(Clin Res Ed) 1984;289:1576–1578. 12. Elsenberg EH, van Werkum JW, van de Wall RM, Zomer AC, Bouman HJ, Verheugt FW, et al. The influence of clinical charasteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb and Haemost 2009; 102:719-727. 13. Kosus N, Kosus A, Turhan N. Mean platelet volume as a marker of future cardiovascular disease risk in pregnant women with impaired fasting glucose and impaired glucose tolerance. Turk J Med Sci 2012; 42:245-51. 14. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103:20-26. 15. Nicholson NS, Panzer Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, et al. Assessment of platelet function assays. Am Heart J 1998; 135:170-78. 16. Katznelson L, Laws Jr RE, Melmed S, Molitch EM, Murad MH, Utz A, and Wass JAH. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014;99: 2014-2700. 17. Lo´pez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moyamur JL, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997; 82:1047-1053. 18. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41:95-102. 19. Pereira AM, van Thiel SW, Lindner JR, Roelfsema R, Ernst E. van der Wal, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89:71-75. 20. Damjanovic SS, Neskovic AN, Petakov MS, Popovic J, Vujisic B, Petrovic M, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med 2002;112:610-6 21. Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, Carolına DI Somma CD, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab 2002;87:3174-3179. 22. Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, et al. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 2006;91:3766-3772. 23. Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol. 2010; 162:879. 24. Rosenfeld ME. Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr Opin Pharmacol 2013; 13: 154-160. 25. Mayer FJ, Hoke M, Schillinger M, Minar E, Arbesu I, Koppensteiner R, et al. Mean platelet volume predicts outcome in patients with asymptomatic carotid artery disease. Eur J Clin Invest 2014; 44:22-28. 26. Hui M, Huandong L, Yu H, Xiaoming L, Wanyuan H, Jin X, et al. Mean Platelet Volume in Relation to Carotid Atherosclerosis in Normotensive, Euglycemic, and Normolipidemic Chinese Middle-Aged and Elderly Adults. Angiology 2014; 65:512-518. 27. Arikan S, Bahceci M, Tuzcu A, Gokalp D. Serum tumour necrosis factor-alpha and interleukin-8 levels in acromegalic patients: acromegaly may be associated with moderate inflammation. Clin Endocrinol (Oxf) 2009; 70: 498-499. 28. Topaloglu O, Sayki AM, Turak O, Ginis Z, Sahin M, Cebeci M, et al. Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol (Oxf) 2014; 80: 726-734 29. Ozkan C, Altinova AE, Cerit ET, Yayla C, Sahinarslan A, Sahin D,et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 2015;18:621-629 30. Unübol M, Güney E, Türe M, Eryılmaz U. Mean platelet volume and arterial stiffness in patients with acromegaly. Anatol J Cardiol 2014; 14: 456-463. 31. Arpaci D, Kuzu F, Unal M, Ilikhan SU, Buyukuysal MC, Bayraktaroglu T. Assessment of Mean Platelet Volume and its Effect on Disease Control in Patients with Acromegaly. Clin Lab. 2016 ;62:2167-2171 32. Ersoy R, Gul K, Solaroglu, Dirikoc A, Aydin C, Soydal C, Cakir B. Effect of a six-month treatment with octreotide long acting repeatable (LAR) on mean platelet volume in patients with acromegaly. Endocrine Abstracts 2008; 16: 431. 33. Lippi G, Salvagno GL, Nouvenne A, Meschi T, Borghi L, Targher G. The mean platelet volume is significantly associated with higher glycated hemoglobin in a large population of unselected outpatients. Prim Care Diabetes 2015; 9: 226-30. 34. Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normoglycemic individuals. Cardiovasc Diabetol 2013; 12: 14. 35. Veeranna V, Zalawadiya SK, Panaich SS, Ramesh K, Afonso L. The association of red cell distribution width with glycated hemoglobin among healthy adults without diabetes mellitus. Cardiology 2012; 122: 129-132 36. Ucler R, Aslan M, Atmaca M, Alay M, Ademoglu EN, Candan Z, et al. The effect of disease control on mean platelet volume and red blood cell distribution in patients with acromegaly. Int J Clin Exp Med 2015; 8:6060-6066.